Feeds
189793 items (189793 unread) in 47 feeds
World Health Organization
(226 unread)
-
WHO news (100 unread)
-
Media
(146891 unread)
-
Reuters Health eLine
(2178 unread)
-
CNN Health (2233 unread)
-
NYT > Health (4529 unread)
-
NPR Health and Science (2963 unread)
-
ABC News: Health (6880 unread)
-
CBSnews.com: Health News (7951 unread)
-
BBC Health News (3350 unread)
-
CBC Health and Science News (2744 unread)
-
Australia ABC News: Health
(4827 unread)
-
China Xinghua Health News
(30 unread)
-
New York Times: Health
(6915 unread)
-
USATODAY.com Health - Top Stories (4435 unread)
-
The Seattle Times: Health (5878 unread)
-
International Herald Tribune: Health and Science (6871 unread)
-
HeraldToday.com: Health
-
WebMD Health Headlines
(5193 unread)
-
MedicineNet Daily News (9287 unread)
-
Medical News Today
(39471 unread)
-
iVillage Health
(5439 unread)
-
Topix.net - Health (5497 unread)
-
Newsvine - health
(20220 unread)
Bird Flu
(3072 unread)
-
MSNBC.com: Bird Flu (14 unread)
-
-
Medical News Today - Bird Flu/Avian Flu
(110 unread)
-
Diabetes
(8450 unread)
-
-
Medical News Today - Diabetes
(2206 unread)
-
Cholesterol
(3575 unread)
-
Topix.net - Cholesterol
(2031 unread)
-
Medical News Today - Cholesterol
(373 unread)
-
Cancer
(15146 unread)
-
-
-
Medical News Today - Breast Cancer News
(1731 unread)
-
Medical News Today - Cancer/Oncology News
(5816 unread)
-
HIV
(7272 unread)
-
-
Medical News Today - HIV/AIDS News
(1910 unread)
-
Women
(3823 unread)
-
-
Medical News Today - OBGYN News
(2595 unread)
-
Men
(1338 unread)
-
-
Medical News Today - Men's health News
(630 unread)
-
Medical News Today - Diabetes (111 unread)
-
Identification Of Key Action Of A Gene Linked To Both Alzheimer's Disease And Type 2 Diabetes
Posted: September 30th, 2010, 3:00am CDT
A research team led by Mount Sinai School of Medicine has identified the mechanism behind a single gene linked to the causes of both Alzheimer's disease and Type 2 diabetes. The data show that a gene for a protein called SorCS1, which can cause Type 2 diabetes, impacts the accumulation of amyloid-beta (Abeta) in the brain. Abeta plays a key role in the development of Alzheimer's disease... -
Diabetes: Mining The 'Wisdom Of Crowds' To Attack Disease
Posted: September 30th, 2010, 3:00am CDT
Crowdsourcing, the act of contracting out problems to large groups rather than tapping individual experts, has solved puzzles in fields such as marketing, engineering and computer software... -
Type 2 Diabetes Study - International Scientific Forum On Alcohol Research
Posted: September 30th, 2010, 2:00am CDT
In a very large cohort of African-American women in the US, the association between the consumption of alcohol, tea, and coffee and the development of type 2 diabetes mellitus (late onset diabetes) was studied for 12 years... -
Rite Aid Joins American Diabetes Association In Fight To Stop Diabetes(R)
Posted: September 29th, 2010, 3:00am CDT
Rite Aid is teaming up with the American Diabetes Association to raise awareness and funds for its national Stop Diabetes campaign, offer incentives for patients to take Diabetes Risk Tests, distribute diabetes guides at every pharmacy counter, and host more than 1,200 free diabetes clinics during American Diabetes Month® in November... -
Scotland Leads The Way In Type 1 Diabetes Research
Posted: September 29th, 2010, 2:00am CDT
Leading health charity Diabetes UK and the Chief Scientist Office of the Scottish Government have announced joint funding of over £675,000 to establish a major resource in Scotland for research into Type 1 diabetes[1]... -
$5 Million Boost For Type 1 Diabetes Research At UC San Diego
Posted: September 29th, 2010, 2:00am CDT
Maike Sander, MD, associate professor of pediatrics and cellular & molecular medicine at the University of California, San Diego School of Medicine has been awarded nearly $5 million by the Beta Cell Biology Consortium (BCBC) to lead an interdisciplinary team in cell therapy research for type 1 diabetes... -
Obese Type 2 Diabetes Patients Have Long-Term Benefits From Intensive Lifestyle Intervention
Posted: September 28th, 2010, 7:00pm CDT
If obese/overweight patients with diabetes Type 2 are helped to get fit, lose weight and control blood glucose levels, their long-term outlook improves significantly, according to a report published in Archives of Internal Medicine... -
Dedicated Foot Clinic Lowers Amputation Incidence In Diabetics
Posted: September 28th, 2010, 3:00pm CDT
A clinic that provides multidisciplinary foot care for diabetic patients may significantly reduce the need for diabetes-related lower-extremity amputations, UK researchers reported here at the 46th European Association for the Study of Diabetes (EASD) meeting... -
News From The Journal Of Clinical Investigation: Sept. 27, 2010
Posted: September 28th, 2010, 5:00am CDT
IMMUNOLOGY: Defective immune cells in patients with type 1 diabetes Studies in mice have defined a subset of immune cells known as HLA-E-restricted CD8+ suppressor (or regulatory) cells as having a role in ensuring that the immune system responds to invading microbes but does not turn on the body to cause autoimmune disease... -
NewYork-Presbyterian Hospital/Weill Cornell Medical Center Launches Educational Program Highlighting Surgical Treatment Of Type 2 Diabetes
Posted: September 28th, 2010, 3:00am CDT
International experts in type 2 diabetes will gather in Rome on September 27-28 to discuss how metabolic surgery may open new treatment opportunities for the disorder, which is on the rise worldwide... -
Diabetics Need Better Grasp Of Hypoglycemia
Posted: September 27th, 2010, 8:00pm CDT
New results show significant knowledge deficits among European patients with type 2 diabetes. The data are from the 2010 Exploring Hypoglycemia Survey, which queried 404 diabetics from five European countries and 250 physicians (either diabetologists or endocrinologists)... -
American Diabetes Association Announces Second Annual John Pipe Voices For Change Award Winners
Posted: September 27th, 2010, 7:00am CDT
The American Diabetes Association, the nation's leading voluntary health organization in the fight against diabetes, announces several leading Special Diabetes Program for Indians (SDPI) grantees presented with the John Pipe Voices For Change Award in recognition of their effective diabetes treatment and prevention services in American Indian and Alaskan Native communities... -
Grant To Study Face-To-Face Vs. Virtual Health Education For African-American Women With Type-2 Diabetes
Posted: September 27th, 2010, 4:00am CDT
BUSM Assistant Dean for Academic Affairs John Wiecha, MD, MPH, in the Department of Family Medicine, has received a National Institutes of Health (NIH) American Recovery & Reinvestment Act (ARRA) Challenge grant from the National Library of Medicine. The grant, valued at more than $950,000 will fund a study to provide health education to African-American women with type-2 diabetes... -
FDA, European Regulators, Restrict Avandia Use
Posted: September 27th, 2010, 3:00am CDT
Wall Street Journal: "The Food and Drug Administration and European regulators said they were taking action on Avandia, made by GlaxoSmithKline PLC, because of data tying it to increased risk of heart attacks... -
Physician Emphasizes Early Recognition Of Type 1 Diabetes; Describes Telltale Signs
Posted: September 26th, 2010, 3:00am CDT
Though they may present in a similar fashion, type 1 diabetes mellitus is vastly different from type 2, and Ralph Schmeltz, MD, incoming president of the Pennsylvania Medical Society, says it's important to recognize and diagnose it early... -
Hormone Foundation Offers Patient Guidance Following FDA Avandia Ruling
Posted: September 26th, 2010, 2:00am CDT
The FDA ruled to keep the glucose control drug Avandia on the market, with significant restrictions. Dr. Robert A. Vigersky, the immediate past president of The Endocrine Society, offers guidance to type 2 diabetes patients in a video interview available on the Hormone Foundation Web site... -
Researchers Unlock Mystery Of Cellular/Molecular Defect That Can Lead To Human Autoimmune Disease
Posted: September 26th, 2010, 2:00am CDT
Researchers at Columbia University Medical Center have identified a defect in the T cell regulatory pathway which normally controls autoreactive T cells that attack the body's own tissues and organs... -
52-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar To Glipizide Plus Metformin In Improving HbA1c
Posted: September 25th, 2010, 4:00am CDT
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) announced results from a randomized, double-blind Phase 3 clinical study in adults with type 2 diabetes inadequately controlled on metformin therapy alone... -
Physician Emphasizes Early Recognition Of Type 1 Diabetes; Describes Telltale Signs
Posted: September 25th, 2010, 3:00am CDT
Though they may present in a similar fashion, type 1 diabetes mellitus is vastly different from type 2, and Ralph Schmeltz, MD, incoming president of the Pennsylvania Medical Society, says it's important to recognize and diagnose it early... -
U.S. Food And Drug Administration Keeps Rosiglitazone (Avandia) On The Market With Restrictions
Posted: September 24th, 2010, 9:00am CDT
The U.S. Food and Drug Administration (FDA) has announced that it will significantly restrict the use of the diabetes drug rosiglitazone (brand name, Avandia) to patients with Type 2 diabetes who cannot control their diabetes on other medications... -
GSK Regulatory Update On Avandia Following EMA And FDA Reviews
Posted: September 24th, 2010, 8:00am CDT
GlaxoSmithKline (NYSE and LSE: GSK) confirms that following a review of Avandia® (rosiglitazone maleate) by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), each agency has announced their individual regulatory decisions and the resulting actions... -
Eli Lilly And Company Encourages African-Americans To Get A Check-up And Face Diabetes
Posted: September 24th, 2010, 8:00am CDT
Angie Stone and Anthony Anderson, spokespeople for Lilly's Fearless African-Americans Connected and Empowered (F.A.C.E.) Diabetes initiative, are teaming up with The Tom Joyner Morning Show (TJMS) for the 9th annual Take a Loved One to the Doctor Day, taking place on September 28, 2010... -
Avandia (Rosiglitazone) To Be Taken Off The Market In Europe
Posted: September 24th, 2010, 8:00am CDT
Avandia (rosiglitazone), and all diabetes medications that contain rosiglitazone will be taken off the market within the next few months, says the European Medicines Agency (EMA) which has recommended taking it off the market. Specifically, the following brands are involved - Avandia, Avandamet and Avaglim... -
Takeda Responds To Announcement About Suspension Of Rosiglitazone Marketing Authorization In Europe And Restrictions In The U.S.
Posted: September 24th, 2010, 7:00am CDT
Following today's announcements by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for rosiglitazone in the U.S. and Europe, Takeda Pharmaceuticals North America, Inc... -
Effective Self-Management Of Blood Glucose Can Be Achieved By Using Meters With Advanced Features Paired With Diabetes Education
Posted: September 24th, 2010, 7:00am CDT
According to a new study, people with diabetes, especially those treated with insulin, may achieve optimal blood sugar control when they understand the impact of food on blood sugar and they utilize useful advanced blood glucose meter (BGM) features such as meal markers and audible reminders... -
Tolerx Presents Research At European Diabetes Meeting And Enrolls First Patient In Europe In The DEFEND-2 Phase 3 Clinical Study In Type 1 Diabetes
Posted: September 24th, 2010, 7:00am CDT
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, announced the presentation of preclinical research describing the mechanism of action of otelixizumab at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD)... -
Unilever Brings Its Expertise To The Diabetes And Cardiovascular Health Challenge In Asia
Posted: September 24th, 2010, 6:00am CDT
Experts on the causes and prevention of diabetes and cardiovascular disease met this week at a symposium organised by Unilever Research and Development and the Singapore agency for Science, Technology and Research, A Star. The symposium, held at Biopolis, Singapore, aimed to understand the health challenges associated with modern lifestyles in Asia... -
Albert Einstein College Of Medicine Researcher To Brief Congressional Staffers On Global Diabetes
Posted: September 24th, 2010, 5:00am CDT
On Monday, September 27, researchers from Albert Einstein College of Medicine of Yeshiva University will hold a congressional briefing in Washington, D.C., aimed at focusing attention on the alarming global diabetes epidemic. Incidence of diabetes is increasing worldwide at a rate that eclipses most other diseases... -
FDA Significantly Restricts Access To The Diabetes Drug Avandia
Posted: September 24th, 2010, 5:00am CDT
The U.S. Food and Drug Administration announced that it will significantly restrict the use of the diabetes drug Avandia (rosiglitazone) to patients with Type 2 diabetes who cannot control their diabetes on other medications. These new restrictions are in response to data that suggest an elevated risk of cardiovascular events, such as heart attack and stroke, in patients treated with Avandia... -
New Study Finds That The Risk Of Cancer In People Using Insulin Is Highest At The Start Of Insulin Treatment And Decreases Over Time
Posted: September 24th, 2010, 4:00am CDT
Researchers from Steno Diabetes Center in Denmark have performed the largest registry linkage study to date focused on diabetes, cancer and insulin use. The study followed the total Danish population, currently 5.5 million people, during 13 years assessing the relationship between duration of insulin use and the occurrence of cancer... -
Chromium Picolinate May Lessen Inflammation In Diabetic Nephropathy
Posted: September 24th, 2010, 2:00am CDT
Taking chromium picolinate may help lessen inflammation associated with diabetic nephropathy (kidney disease), say researchers at the Medical College of Georgia in Augusta... -
Boston Scientific's TAXUS(R) Element™ Stent Demonstrates Strong Outcomes In Diabetic Patients
Posted: September 24th, 2010, 2:00am CDT
Boston Scientific Corporation (NYSE: BSX) announced results from an analysis of 1,166 patients from its PERSEUS clinical program comparing the performance of the TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System in diabetic versus non-diabetic patients... -
Avandia (rosiglitazone) Use To Be Severely Restricted
Posted: September 23rd, 2010, 2:00pm CDT
The use of diabetes medication, Avandia (rosiglitazone) is to be significantly restricted to patients with diabetes Type 2 who are unable to control their diabetes on other drugs, the Food and Drug Administration (FDA) has announced. FDA officials say this is after evaluating data which links Avandia to a higher risk of stroke and cardiovascular events, such as heart attack... -
Sanuwave Completes Patient Follow-Up In Phase III Trial Of Dermapace For The Treatment Of Diabetic Foot Ulcers
Posted: September 23rd, 2010, 5:00am CDT
SANUWAVE Health, Inc... -
Pilot Study Demonstrates Safety Of Diabetes Medication For Patients With Alzheimer's Disease
Posted: September 23rd, 2010, 4:00am CDT
A pilot study suggests the diabetes medication pioglitazone is generally well tolerated and may warrant further study as a treatment for patients with Alzheimer's disease, according to a report posted online today that will appear in the January 2011 print issue of Archives of Neurology, one of the JAMA/Archives journals... -
New Head-to-head Data For Long-acting Insulin Degludec Show Lower Day-to-day Variability Compared To Insulin Glargine
Posted: September 23rd, 2010, 3:00am CDT
Novo Nordisk presented new phase 2 head-to-head glucose clamp data for its investigational insulin degludec, a long-acting basal insulin which provided significantly lower day-today variability and offered a more stable glucose-lowering insulin effect in people with type 1 diabetes than insulin glargine... -
PROMUS(R) Element™ Stent Approved For Use In Diabetic And Heart Attack Patients In CE Mark Countries
Posted: September 23rd, 2010, 2:00am CDT
Boston Scientific Corporation (NYSE: BSX) announced that its PROMUS® Element™ Everolimus-Eluting Coronary Stent System has received CE Mark approval for use in patients with diabetes(1) and those experiencing an acute myocardial infarction (AMI), or heart attack. "We are pleased to receive these expanded indications for the high-risk diabetic and AMI patient groups," said Keith D... -
South Asians In US At Higher Diabetes Risk Than Other Asian Immigrants
Posted: September 23rd, 2010, 2:00am CDT
South Asians living in the United States are at much higher risk for type 2 diabetes than are whites and immigrants from other Asian countries, a new small study reveals. The study classified Asians born in Bangladesh, India, Nepal and Pakistan as South Asians... -
Albert Einstein College Of Medicine Researcher To Brief Congress On Global Diabetes
Posted: September 23rd, 2010, 2:00am CDT
On Monday, September 27, researchers from Albert Einstein College of Medicine of Yeshiva University will hold a congressional briefing in Washington, D.C., aimed at focusing attention on the alarming global diabetes epidemic. Incidence of diabetes is increasing worldwide at a rate that eclipses most other diseases... -
New Phase III Data Further Support The Safety And Efficacy Profile Of Boehringer Ingelheim's Investigational Drug Linagliptin
Posted: September 23rd, 2010, 2:00am CDT
New data from the linagliptin late stage clinical trial programme were presented this week at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD)... -
The Uptake Of Key Agents Such As Januvia, Bydureon And Byetta Will Drive The Type 2 Diabetes Drug Market To Increase From $19 Billion To $36 Billion
Posted: September 22nd, 2010, 8:00am CDT
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continued uptake of key agents such as Merck's Januvia, Eli Lilly/Amylin/Alkermes' Bydureon and Amylin/Eli Lilly's Byetta will drive the type 2 diabetes drug market to nearly double from $19 billion in 2009 to $36 billion in 2019 in the United Stat... -
New Global Survey Reveals Over One In Three Patients Fail To Take Insulin As Prescribed
Posted: September 22nd, 2010, 8:00am CDT
More than one in three diabetes patients skip doses or fail to take their insulin as prescribed, stating that they have done so on average three times in the last month, and 77 percent of physicians estimate that in reality this number could be as high as six doses, according to the Global Attitudes of Patients and Physicians in Insulin Therapy (GAPP™) survey, released by Novo Nordisk... -
USPTO Awards Key Patent For New Syringe Injection System, ConfiDisc(R)
Posted: September 22nd, 2010, 8:00am CDT
Product innovators Chris and Sonia Hillios are pleased to announce that they have been granted a patent by the U.S. Patent and Trademark Office pertaining to their new syringe injection system, ConfiDisc(R). The patent covers the innovator's syringe injection system, which enables users to achieve the correct angle and depth of subcutaneous and intramuscular injections... -
ChemoCentryx Reports Positive Results And Completion Of Phase I Clinical Studies Of Novel CCR2 Antagonist, CCX140
Posted: September 22nd, 2010, 7:00am CDT
ChemoCentryx, Inc., announced that it reported positive preclinical and Phase I study results at the European Association for the Study of Diabetes (EASD)... -
Results Of Linjeta™ Study Versus Insulin Lispro Reported In The Platform Presentation At EASD Annual Meeting
Posted: September 22nd, 2010, 7:00am CDT
In a platform presentation at the 46th annual meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, investigators for Biodel Inc. (Nasdaq: BIOD) presented the results of a clinical study evaluating a new pH-neutral formulation of Linjeta™ (VIAject®). Dr... -
In Pregnancy, A Large Waistline And High Triglycerides: Early Screen For Gestational Diabetes
Posted: September 22nd, 2010, 3:00am CDT
A large waistline and high triglyceride levels in pregnant women could be an early screening tool for gestational diabetes, according to a study published in CMAJ (Canadian Medical Association Journal)... -
24-Week Phase 3 Study Found Investigational Drug Dapagliflozin Improved Glycosylated Hemoglobin (HbA1c) When Added To Glimepiride
Posted: September 21st, 2010, 4:00am CDT
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) announced results from a randomized, double blind Phase 3 clinical study, which demonstrated that the addition of the investigational drug dapagliflozin to existing glimepiride (sulphonylurea) therapy produced significant reductions in glycosylated hemoglobin levels (HbA1c) in adult patients with type 2 diabet... -
Understanding Patients' Needs In Order To Simplify Life With Diabetes
Posted: September 21st, 2010, 4:00am CDT
Lack of proper information, motivational obstacles and behavioral skill limitations are the most influential factors that prevent people with diabetes from adhering to self-monitoring of blood glucose (SMBG) as recommended by their health care providers. That is why a patient-focused approach in diabetes therapy is of pivotal importance to improve compliance and treatment outcomes... -
NICE Consults On The Management Of Diabetic Foot Problems
Posted: September 21st, 2010, 3:00am CDT
NICE has opened a consultation on its draft guidelines for the care of people with diabetic foot problems in hospital. Diabetes is one of the greatest health problems facing the UK today. In 2009, it was estimated that there were 2.6 million people in the UK with type 1 or type 2 diabetes[1]. With the increasing prevalence of the condition, the incidence of complications is also on the rise... -
Adding Lantus® To Oral Antidiabetic Drug Therapy Further Reduced Blood Sugar In Patients With Type 2 Diabetes
Posted: September 21st, 2010, 3:00am CDT
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced results of two studies presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden... -
Kids And Diabetes Risk: Do Chromosomes Hold New Clues?
Posted: September 21st, 2010, 2:00am CDT
Children who have a high risk of developing type 2 diabetes might be identified earlier by way of tell-tale genetic indicators known as biomarkers. Some of those new biomarkers might be pinpointed in research led by Nancy F. Butte and funded by the U.S. Department of Agriculture (USDA) and the U.S. Department of Health and Human Service's National Institutes of Health... -
New Drug A Potential Treatment For Type 2 Diabetes
Posted: September 21st, 2010, 2:00am CDT
Australian scientists, in association with US pharmaceutical company DiaKine Therapeutics, have shown that a drug candidate, Lisofylline, could be useful in treating Type 2 diabetes... -
Investigational Drug Dapagliflozin For Diabetes Meets Study Goals After 24-Week Phase 3 Study
Posted: September 20th, 2010, 12:00pm CDT
Dapagliflozin when added to existing glimepiride (sulphonylurea) therapy significantly reduced HbA1C (glycosylated hemoglobin) in adults with Type 2 Diabetes, compared to patients taking glimepiride plus a placebo, a 24-week Phase 3 Study revealed. In a joint announcement, Astra Zeneca PLC. and Bristol-Myers Squibb Company said the trial met the study goals... -
Sitagliptin Rivals Glimepiride For Glycemic Control With Less Hypoglycemia And No Weight Gain
Posted: September 20th, 2010, 8:00am CDT
The addition of the highly selective, once-daily dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin (Januvia), compared with glimepiride (Amaryl), to background metformin therapy provides similar glycemic control in type 2 diabetics but, importantly, produces significantly fewer hypoglycemic episodes and also results in weight loss, new data show... -
Women With Diabetes Having More C-Sections And Fetal Complications: Study
Posted: September 20th, 2010, 6:00am CDT
Nearly half of women with diabetes prior to pregnancy have a potentially-avoidable C-section and their babies are twice as likely to die as those born to women without diabetes, according to the POWER study. Researchers from St... -
Biochemical Link Between Biological Clock And Diabetes Discovered
Posted: September 20th, 2010, 5:00am CDT
Biologists have found that a key protein that regulates the biological clocks of mammals also regulates glucose production in the liver and that altering the levels of this protein can improve the health of diabetic mice... -
Scientists Develop Test Providing New Pathway For Identifying Obesity, Diabetes Drugs
Posted: September 19th, 2010, 2:00am CDT
Scientists at The Scripps Research Institute have designed a new molecular test that will allow researchers to look for potential drugs targeting a human metabolic enzyme believed to stimulate the appetite and play a role in diabetes... -
Free Diabetes Risk Assessment Tool Available To Healthcare Professionals
Posted: September 19th, 2010, 2:00am CDT
The 'Diabetes Risk Score' is a risk assessment tool designed to identify those at high risk of impaired glucose regulation ('prediabetes') and Type 2 diabetes... -
AHRQ News And Numbers: Diabetes Pills Use Up; Insulin Use Down
Posted: September 19th, 2010, 2:00am CDT
The proportion of Americans reporting treatment for diabetes who took oral medications to treat their condition increased from 60 percent in 1997 to 77 percent in 2007 - a 28 percent increase - according to the latest News and Numbers from the Agency for Healthcare Research and Quality... -
Diabetes Drug Actos (pioglitazone) Review Initiated To Determine Possible Bladder Cancer Link
Posted: September 18th, 2010, 12:00pm CDT
Actos (pioglitazone), a diabetes medication is being reviewed by the FDA (Food and Drug Administration) after it received a long-term observational study which evaluated the risk of bladder cancer. The preliminary results of the 10-year observational long-term study are based on five-year data gathered by Takeda Pharmaceuticals North America Inc., San Diego... -
FDA Reviewing Preliminary Safety Information On Actos (pioglitazone)
Posted: September 18th, 2010, 4:00am CDT
The U.S. Food and Drug Administration announced it has begun a safety review of the diabetes drug Actos (pioglitazone), after receiving preliminary results from a long-term observational study designed to evaluate the risk of bladder cancer associated with use of this drug... -
Practical Diabetology Highlights Advanced Lipid Testing For Type 2 Diabetes Patients
Posted: September 18th, 2010, 4:00am CDT
The article discusses the clinical advantages of advanced cholesterol testing in reducing cardiovascular disease (CVD) risk in patients with Type 2 diabetes and details several currently available advanced lipid tests, including the VAP® Cholesterol Test from Atherotech. Cobble also explores which patients are appropriate to test and how to apply advanced lipid testing results... -
Diabetes And Hearing Loss, A Message Often Unheard
Posted: September 18th, 2010, 4:00am CDT
HearPO is proud to announce a National Strategic Partnership with the American Diabetes Association. This National Strategic Partnership will provide additional resources and avenues to educate people with diabetes, medical practitioners and the general public about the connection between diabetes and hearing loss... -
NIH-Funded Beta Cell Biology Consortium Aims To Eliminate Daily Insulin Injections, Finger Pricks
Posted: September 18th, 2010, 2:00am CDT
Oregon Health & Science University's Markus Grompe, M.D., will lead a multi-center team of scientists selected to participate in the prestigious Beta Cell Biology Consortium (BCBC). Funded by the National Institute of Diabetes and Digestive and Kidney Diseases, the consortium's long-term goal is to develop a cell-based therapy for insulin delivery in type 1 diabetes patients... -
Emory Researchers Say Chronic Diseases A Global Problem Requiring Global Solutions
Posted: September 18th, 2010, 2:00am CDT
Policymakers should increase their sense of urgency to stop the global spread of chronic diseases such as heart disease, cancer and diabetes that threaten the health and economies of industrialized and developing nations alike, Emory University global health researchers say. Writing in the current issue of The New England Journal of Medicine, authors K. M... -
New Blood Markers For Diabetes May Help To Identify Patients At Risk
Posted: September 17th, 2010, 8:00am CDT
For the first time, scientists have found that blood levels of some ribonucleic acids (microRNAs) are different among people with type 2 diabetes and those who subsequently develop the disease compared to healthy controls, according to research reported in Circulation Research: Journal of the American Heart Association... -
Metabolic Solutions Development Company To Present Research Findings To European Association For The Study Of Diabetes
Posted: September 17th, 2010, 6:00am CDT
Metabolic Solutions Development Company (MSDC), will present research at the European Association for the Study of Diabetes (EASD) annual conference in Stockholm, Sweden on Sept. 23, 2010. The research indicates that the company's clinical candidate, MSDC-0160, promotes the proliferation of stem cells that create brown fat, leading to the creation of more brown fat... -
Artificial Pancreas Gives Hope To Diabetes Sufferers
Posted: September 17th, 2010, 4:00am CDT
A researcher has developed an artificial pancreas that she says could revolutionise the treatment of diabetes. The device, developed by Professor Joan Taylor from De Montfort University, Leicester, could even put an end to daily injections diabetics have to endure to regulate their glucose levels... -
FDA Panel Says No To New Obesity Drug Lorcaserin
Posted: September 17th, 2010, 4:00am CDT
A US Food and Drug Administration (FDA) advisory committee has voted against recommending federal approval of the new obesity drug lorcaserin, made by Arena Pharmaceuticals Inc under the brand name Lorqess, making it the third time this year that an obesity drug has failed to get the thumbs up from the panel... -
Potential For New Immune System-Based Therapies
Posted: September 17th, 2010, 3:00am CDT
A new focus on the immune system's ability to both unleash and restrain its attack on disease has led Dana-Farber Cancer Institute scientists to identify cells in mice that prevent the immune system from attacking the animals' own cells, protecting them from autoimmune diseases such as multiple sclerosis, type 1 diabetes, and lupus. The discovery, reported online on Sept... -
What Your Family Isn't Talking About Can Hurt You - American Diabetes Association
Posted: September 17th, 2010, 2:00am CDT
Good food, good music, and good conversation -- three key ingredients to many Hispanic/Latino family gatherings. But what is missing from many of those get-togethers is a life-saving conversation about the family's medical history... -
Community Diabetes Education May Help Latinos
Posted: September 16th, 2010, 6:00am CDT
A diabetes self-management education program delivered by community health workers may be effective in improving the blood sugar levels and behavioral skills among Hispanics/Latinos with type 2 diabetes, according to a recent University of Illinois at Chicago study... -
Derma Sciences To Complete Enrollment In DSC127 Phase 2 Wound Healing Trial This Month
Posted: September 16th, 2010, 5:00am CDT
Derma Sciences, Inc. (Nasdaq:DSCI), a medical device and pharmaceutical company focused on advanced wound care, announced that patient screening in its DSC127 Phase 2 trial in diabetic foot ulcer healing will be completed tomorrow, and that enrollment in the trial will conclude on September 30... -
TransPharma Announces Successful Completion Of Phase 1a Clinical Trial Of ViaDerm-GLP1 Agonist Indicated For The Treatment Of Type II Diabetes
Posted: September 16th, 2010, 5:00am CDT
TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of a Phase 1a trial of ViaDerm-GLP1 agonist which is being developed for the treatment of diabetes mellitus type II... -
Regenerative Medicines For Diabetic Retinopathy To Be Developed By AstraZeneca And UCL Collaboration
Posted: September 15th, 2010, 7:00am CDT
AstraZeneca and UCL have entered into a collaboration to develop regenerative medicines for diabetic retinopathy (DR). DR is now the most common cause of vision impairment among people of working age in Western society. The majority of patients with type 1 diabetes will develop retinopathy and about 20-30% will become blind... -
NIH Awards $8 Million To UT Southwestern To Study Metabolism, Obesity-Related Inflammation
Posted: September 15th, 2010, 7:00am CDT
An $8 million grant from the National Institutes of Health will enable UT Southwestern Medical Center to investigate how fat tissue "talks" to the brain and the liver to promote inflammation-related disorders such as diabetes, heart disease and obesity... -
BYETTA® And BYDUREON™ To Be Featured In More Than A Dozen Study Presentations At EASD 2010
Posted: September 15th, 2010, 6:00am CDT
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc... -
Oramed Pharmaceuticals Announces Successful Results Of A Novel Exploratory Clinical Study Of Its Flagship Oral Insulin Capsule
Posted: September 15th, 2010, 5:00am CDT
Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) announced successful results in an exploratory clinical trial testing the effectiveness of its oral insulin capsule (ORMD-0801) in Type I diabetes patients suffering from uncontrolled diabetes... -
Arcion Therapeutics Receives FDA Fast Track Designation For ARC-4558 For The Treatment Of Pain Associated With Painful Diabetic Neuropathy
Posted: September 15th, 2010, 5:00am CDT
Arcion Therapeutics, a venture backed clinical stage biotechnology company developing topical therapies for chronic pain, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARC-4558 for the treatment of pain associated with Painful Diabetic Neuropathy (PDN). ARC-4558 is a 0.1% gel formulation of clonidine hydrochloride for topical administration... -
Congressman To Speak At Meeting On Diabetes And Obesity
Posted: September 15th, 2010, 4:00am CDT
U.S. Rep. Danny Davis (D-Chicago) will give opening remarks when the Institute of Medicine of the National Academies convenes a regional meeting Sept. 21 at the University of Illinois at Chicago to discuss the rapidly rising rates of diabetes and obesity in the U.S. "Obesity and diabetes are grave public health issues for our communities, particularly in underserved populations," Davis said... -
News From The Annals Of Family Medicine: September/October 2010
Posted: September 15th, 2010, 2:00am CDT
Low Adherence with Regular Fecal Occult Blood Test Screening Among Insured Patients In a large U.S. health plan, nearly one-half of patients who initiated biennial fecal occult blood test (FOBT) screening did not adhere to subsequent colorectal screening in the ensuing 2-year period, compromising the effectiveness of the screening endeavor which hinges on regular screening... -
Experimental Diabetes Drug Taspoglutide Late-Stage Trials Suspended
Posted: September 13th, 2010, 12:00pm CDT
Experimental diabetes drug, taspoglutide, a joint development between Roche (Switzerland) and Ipsen (France), had its late-stage trials suspended because of side effects. Roche announced that it had stopped giving patients taspoglutide because of adverse gastrointestinal reactions. The drug already has some "hypersensitivity problems"... -
Drug Halts And Can Even Reverse Diabetic Peripheral Neuropathy In Mice
Posted: September 13th, 2010, 2:00am CDT
A drug developed at the University of Kansas has the potential to stop a debilitating condition of diabetes that often leads to pain in the extremities and even amputations, KU researchers have found. The researchers recently published an article showing that KU-32 can stop and even reverse diabetic peripheral neuropathy, or DPN, in mice... -
Diabetes Information In Twenty Languages
Posted: September 12th, 2010, 2:00am CDT
Leading health charity Diabetes UK now has a range of diabetes literature in twenty different languages. The charity has focussed on materials in many Eastern European languages as well as Chinese, Somali, Arabic, and the main South Asian languages. The charity has done this to ensure communities at high risk of diabetes can access this vital information... -
Heart Institute Study Finds Strong Link Between Obesity, High Blood Pressure, Diabetes
Posted: September 11th, 2010, 2:00am CDT
New analysis of a landmark health survey by the University of Ottawa Heart Institute (UOHI) shows that 70% of Ontario adults are either overweight or obese, and have a strong prevalence of high blood pressure that could lead to heart attack or stroke. The research, led by Dr... -
NICE Recommends Liraglutide For Type 2 Diabetes Mellitus
Posted: September 10th, 2010, 8:00am CDT
In draft guidance published today (10 September 2010), NICE recommends liraglutide[[1]] (Victoza, Novo Nordisk) 1.2 mg daily for some people with type 2 diabetes mellitus. However, it does not recommend liraglutide at 1.8mg daily, as the available evidence does not suggest any significant additional benefit with the higher dose. Liraglutide 1... -
Santarus Licenses Novel Type 2 Diabetes Drug CYCLOSET
Posted: September 10th, 2010, 4:00am CDT
Santarus, Inc. (NASDAQ: SNTS), S2 Therapeutics, Inc. and VeroScience LLC today announced that they have entered into a distribution and license agreement granting Santarus exclusive rights to manufacture and commercialize CYCLOSET® (bromocriptine mesylate) tablets in the U.S. CYCLOSET is a prescription drug approved by the U.S... -
The Safety Questioned Of Certain 'Healthful' Plant-Based Antioxidants
Posted: September 10th, 2010, 3:00am CDT
Scientists are calling for more research on the possibility that some supposedly healthful plant-based antioxidants - including those renowned for their apparent ability to prevent cancer - may actually aggravate or even cause cancer in some individuals... -
Several Inflammatory Factors Induced By Bacterial Infection May Be Reduced By Insulin
Posted: September 10th, 2010, 3:00am CDT
Treating intensive care patients who develop life-threatening bacterial infections, or septicemia, with insulin potentially could reduce their chances of succumbing to the infection, if results of a new preliminary study can be replicated in a larger study... -
NICE Issues Its Final Appraisal Determination (FAD) On The Use Of Victoza(R) (liraglutide) For People With Type 2 Diabetes In The UK
Posted: September 10th, 2010, 3:00am CDT
Today, as part of its Single Technology Appraisal (STA), the National Institute for Health and Clinical Excellence (NICE), issued its Final Appraisal Determination (FAD) on the use of Victoza® (liraglutide)1 for patients with type 2 diabetes in the UK... -
Liraglutide (Victoza) For Diabetes Type Two Approved For The NHS, UK
Posted: September 10th, 2010, 3:00am CDT
The National Institute for Clinical Excellence (NICE), in a draft guidance has recommended Liraglutide (Victoza) 1.2mg injectable daily for some patients with diabetes mellitus type 2. NICE does not, however, recommend the 1.8mg daily dosage, saying there does not appear to be any significant additional benefit over the 1.2mg dose. NICE recommends Liraglutide 1... -
How Insulin Stimulates Fat Cells To Take In Glucose
Posted: September 10th, 2010, 2:00am CDT
Using high-resolution microscopy, researchers at the National Institutes of Health have shown how insulin prompts fat cells to take in glucose in a rat model. The findings were reported in the Sept. 8 issue of the journal Cell Metabolism. By studying the surface of healthy, live fat cells in rats, researchers were able to understand the process by which cells take in glucose... -
CHMP Meets To Discuss Avandia And Pandemrix, Europe
Posted: September 9th, 2010, 5:00am CDT
The Committee for Medicinal Products for Human Use (CHMP) met on Wednesday 8 September to discuss the ongoing benefit-risk review of the rosiglitazone-containing medicines Avandia, Avandamet and Avaglim... -
Insulin Implicated In Cell Survival, Cell Metabolism And Stress Response
Posted: September 9th, 2010, 2:00am CDT
Researchers at the Buck Institute for Age Research have discovered a novel way in which insulin affects cell metabolism and cell survival. Surprisingly the insulin signaling pathway, which is involved in aging, diabetes and stress response, is active at a deeper level of cell activity than scientists expected. The study appears in the September 8th issue of Cell Metabolism... -
Risk Of Gestational Diabetes, Cesarean Section, Reduced In The Obese By Bariatric Operations
Posted: September 9th, 2010, 2:00am CDT
Obese women who have bariatric surgical procedures before pregnancy were three times less likely to develop gestational diabetes (GDM) than women who have bariatric operations after delivery, according to new research findings published in the August issue of the Journal of the American College of Surgeons... -
Survey Data Reveals Shocking 'Insulin Pump Postcode Lottery'
Posted: September 8th, 2010, 8:00am CDT
A comprehensive new survey of all 152 PCTs undertaken and published by the Medical Technology Group (MTG), backed by national diabetes support groups INPUT, the Juvenile Diabetes Research Foundation (JDRF), clinicians and leading cross-party MPs, has exposed major inequities in care for patients with diabetes across the country... -
AHRQ Releases New Spanish Language Guides For Patients
Posted: September 8th, 2010, 5:00am CDT
HHS' Agency for Healthcare Research and Quality today released a series of free evidence-based guides designed to help Spanish speakers understand and compare the risks, benefits and side effects of treatments for eight health conditions. The guides provide valuable information that patients can use in talking with their clinicians... -
Short Sleepers At Higher Risk Of Type 2 Diabetes And Heart Disease
Posted: September 8th, 2010, 4:00am CDT
People who sleep less than six hours a night may be three times more likely to develop a condition which leads to diabetes and heart disease, according to researchers at the University of Warwick... -
Epitwin: Largest Ever Epigenetics Project Launched
Posted: September 7th, 2010, 4:00am CDT
One of the most ambitious large-scale projects in Human Genetics has been launched: Epitwin will capture the subtle epigenetic signatures that mark the differences between 5,000 twins on a scale and depth never before attempted, providing key therapeutic targets for the development of drug treatments... -
Concern About Rosiglitazone (Avandia) And How Drugs Are Regulated And Promoted, BMJ
Posted: September 6th, 2010, 1:00pm CDT
There is serious concern about top-selling diabetes drug rosiglitazone (Avandia), its safety, as well as the whole system by which medications are regulated, evaluated and promoted worldwide, according to a BMJ (British Medical Journal) investigation. Dr. Fiona Godlee, BMJ Editor-in-Chief, thinks Avandia should not have been licensed; she believes it should be withdrawn... -
Vended Foods And Beverages May Be Linked To Obesity, Diabetes And Coronary Artery Disease
Posted: September 6th, 2010, 2:00am CDT
School children who consume foods purchased in vending machines are more likely to develop poor diet quality - and that may be associated with being overweight, obese or at risk for chronic health problems such as diabetes and coronary artery disease, according to research from the University of Michigan Medical School... -
Pediatric Weight Expert Provides Obesity Trinity Answers
Posted: September 6th, 2010, 2:00am CDT
In a first person paper published in the August 27, 2010 issue of Childhood Obesity, Dr. Melinda Sothern, Director of Health Promotion and Professor of Public Health at LSU Health Sciences Center New Orleans, provides three ways to de-program the 1950s obesity trinity underlying the current obesity epidemic in the United States and protect future generations from its health consequences... -
Why Fish Oils Work Swimmingly Against Diabetes
Posted: September 3rd, 2010, 6:00am CDT
Researchers at the University of California, San Diego School of Medicine have identified the molecular mechanism that makes omega-3 fatty acids so effective in reducing chronic inflammation and insulin resistance. The discovery could lead to development of a simple dietary remedy for many of the more than 23 million Americans suffering from diabetes and other conditions... -
Halozyme Begins Phase 2 Clinical Trials With Insulin Analogs Lispro And Aspart With RHuPH20 In Type 1 And Type 2 Diabetes
Posted: September 3rd, 2010, 4:00am CDT
Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealtime analogs: insulin aspart, the active ingredient in NovoLog®, and insulin lispro, the active ingredient in Humalog®... -
News From The Journal Of Clinical Investigation: Sept. 1, 2010
Posted: September 3rd, 2010, 2:00am CDT
INFECTIOUS DISEASE: Modified adenovirus malaria vaccine works a treat in mice Malaria kills more than 1 million individuals each year. Despite intensive research, there is still no malaria vaccine approved for use. A team of researchers, led by Moriya Tsuji, at the Aaron Diamond AIDS Research Center, New York, has now designed a new vaccine that provides protection from malaria in mice... -
Diabetes 2 Drug Metformin May Protect Against Lung Cancer In Smokers
Posted: September 2nd, 2010, 8:00am CDT
Two studies reveal that smokers may have a significantly lower risk of developing lung cancer and colorectal cancer with the drug metformin, which is commonly prescribed for diabetes type 2 treatment, the medical journal Cancer Prevention Research informs... -
More Patients Research Their Own Diseases, Seek To Manage Chronic Conditions
Posted: September 2nd, 2010, 6:00am CDT
News outlets report on how the delivery of health care is being changed by empowered patients. USA Today: "In the past, most patients placed their entire trust in the hands of their physician. Your doc said you needed a certain medical test, you got it. Not so much anymore. Though some doctors find the newer 'empowered' patients taxing, others ... -
pSivida Announces Iluvien(R) Receives FDA Priority Review For Treatment Of Diabetic Macular Edema
Posted: September 2nd, 2010, 3:00am CDT
pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, announced that its licensee, Alimera Sciences (NASDAQ:ALIM) has been notified that the U.S... -
New Study Singles Out Factors Linked To Cognitive Deficits In Type 2 Diabetes
Posted: September 2nd, 2010, 3:00am CDT
Older adults with diabetes who have high blood pressure, walk slowly or lose their balance, or believe they're in bad health, are significantly more likely to have weaker memory and slower, more rigid cognitive processing than those without these problems, according to a new study published by the American Psychological Association... -
Experts Wonder Why Slimming Drug Meridia (sibutramine) Is Still On The Market In USA
Posted: September 2nd, 2010, 3:00am CDT
Sibutramine, brand name Meridia is an appetite suppressant, a weight loss pill. Editors at the NEJM (New England Journal of Medicine) write it is difficult for them to discern a "credible rationale for keeping this medication on the market", even though it is restricted for people without heart disease... -
Growing Obesity, Diabetes Epidemics In California
Posted: September 2nd, 2010, 2:00am CDT
A majority of adults in California are obese or overweight, and more than 2 million have been diagnosed with diabetes, according to a new study from the UCLA Center for Health Policy Research...